RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine

Abstract

BackgroundThe usefulness of ribonucleotide reductase catalytic subunit M1 (RRM1) for predicting the therapeutic effects of gemcitabine-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. RRM1-positive patients show unique clinicopathological features.MethodsHere, we performed a meta-analysis to systematically evaluate the relationship between RRM1 expression and the clinicopathological characteristics of NSCLC patients treated with gemcitabine-containing regimens. A comprehensive electronic and manual search was performed to identify relevant articles. The pooled relative risk (RR) and 95% CI were used to estimate the relation between the clinicopathological characteristics of NSCLC patients and RRM1 expression.ResultsThe study included 31 observational studies and 3,667 patients. The analysis showed no significant association between RRM1 expression and pathological type, stage, and smoking status; however, RRM1 positivity was significantly lower in women than in men (43.0% vs 51.7%, RR=0.84, 95% CI: 0.74–0.94, P=0.004).ConclusionThe present pooled analyses demonstrated that RRM1 positivity in women with advanced NSCLC was associated with a higher rate of response to gemcitabine-containing regimens. Immunohistochemistry may be valuable to prescreen for RRM1 expression in clinical practice, whereas PCR can be routinely used as a verification method. These findings will help design suitable molecular-targeted therapies for NSCLC.

Prognostic and predictive role of a metabolic rate‐limiting enzyme signature in hepatocellular carcinoma

“…RRM1 could regulate metabolization and activity of mitotane 23 . Previous research has demonstrated that higher RRM1 expression is discovered to associated with shorter overall survival in non‐small cell lung cancer (NSCLC), 24 non‐muscle‐invasive bladder cancer (NMIBC) 25 and multiple myeloma patients 26 . UCK2 could convert uridine and cytidine to uridine monophosphate (UMP) and cytidine monophosphate (CMP), promoting metastasis of HCC cells via the STAT3/MMP2/MMP9 signal axis 27 .…”

Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer

“…Recent studies have demonstrated that upregulation of RRM1 has been observed in various cancers, including liver cancer [24,[31][32][33]. The high expression of RRM1 was associated with resistance to DNA-damaging platinum drugs, leading to worse outcomes [34,35].…”

Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer

“…RRM1 is an important molecular target of gemcitabine because it can control the specificity of a substrate and the activity of an enzyme. Patients with low RRM1 expression had a relatively long survival times after chemotherapy [ 11 , 12 ]. In NMIBC patients treated with intravesical gemcitabine monotherapy, low RRM1 expression patients had longer progression-free survival and lower 1-year/2-year relapse rates, although there is a need to further verify the results [ 13 ].…”